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Abstract
Purpose To evaluate the feasibility of PET/MRI (positron
emission tomography/magnetic resonance imaging) with
FDG (18F-fluorodeoxyglucose) for initial staging of head
and neck cancer.
Methods The study group comprised 20 patients (16 men, 4
women) aged between 52 and 81 years (median 64 years)
with histologically proven squamous cell carcinoma of the
head and neck region. The patients underwent a PET scan
on a conventional scanner and a subsequent PET/MRI ex-
amination on a whole-body hybrid system. FDG was ad-
ministered intravenously prior to the conventional PET scan
(267–395 MBq FDG, 348 MBq on average). The maximum
standardized uptake values (SUVmax) of the tumour and of
both cerebellar hemispheres were determined for both PET
datasets. The numbers of lymph nodes with increased FDG
uptake were compared between the two PET datasets.
Results No MRI-induced artefacts where observed in the
PET images. The tumour was detected by PET/MRI in 17
of the 20 patients, by PET in 16 and by MRI in 14. The PET/
MRI examination yielded significantly higher SUVmax than
the conventional PET scanner for both the tumour (p<
0.0001) and the cerebellum (p00.0009). The number of
lymph nodes with increased FDG uptake detected using
the PET dataset from the PET/MRI system was significantly
higher the number detected by the stand-alone PET system
(64 vs. 39, p00.001).
Conclusion The current study demonstrated that PET/MRI
of the whole head and neck region is feasible with a whole-
body PET/MRI system without impairment of PET or MR
image quality.
Keywords PET/MRI . Head and neck cancer
Introduction
Head and neck cancer ranks among the ten most common
malignant diseases [1]. The vast majority of head and neck
malignancies are squamous cell carcinomas [2]. The choice
of therapy in patients with head and neck cancer depends
mainly on tumour location, the invasion of adjacent struc-
tures and on the presence of metastases [3]. MRI provides
excellent soft tissue contrast, which is useful for differenti-
ating masses from neighbouring tissues and has facilitated
the widespread use of MRI for head and neck imaging. MRI
is considered the modality of choice for imaging tumours of
the oral cavity [4] and the pharynx [5]. However, the sensi-
tivity of MRI for metastatic lymph node disease is rather
low, as it relies on morphologic criteria for lymph node
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evaluation [6]. 18F-Fluorodeoxyglucose (FDG) PET has
superior sensitivity for the detection of cervical lymph node
metastases in comparison with both CT and MRI [7, 8]. The
recently introduced whole-body PET/MRI systems [9] com-
bine the unique metabolic imaging capabilities of PET with
the superb soft tissue contrast of MRI. PET/MRI thus
appears to be a promising modality for the imaging of head
and neck malignancies. The aim of this pilot study was to
evaluate the feasibility of FDG-PET/MRI for initial staging
of head and neck cancer.
Materials and methods
Patients
The study was approved by the local ethics committee and
all patients gave written informed consent before being
included. The study group comprised 20 patients (16 men,
4 women) aged between 52 and 81 years (median age
64 years) with histologically proven squamous cell carcino-
ma of the head and neck region. The patients were examined
using both a stand-alone PET scanner and a whole-body
PET/MRI system. Tumour locations included the floor of
the mouth (six patients), tongue (five), mandible (three),
lower lip (two), maxillary sinus (one), piriform sinus
(one), maxilla (one) and the palatine tonsils (one).
PET
The patients were instructed to refrain from food intake for
at least 6 h before FDG injection, while fluid intake (water
or tea without sugar) was encouraged. PET imaging was
performed with a dedicated PET scanner (ECAT EXACT
HR+; Siemens, Erlangen, Germany; axial field of view of
15.25 cm, reconstructed isotropic spatial resolution about
6.5 mm). The scanner’s septa allowed examinations in either
2D or 3D mode. Prior to the examination, 4.5 MBq 18F-
FDG/kg body weight was administered intravenously (267–
395 MBq 18F-FDG per patient, 348 MBq on average; in-
house production) [10]. The time between tracer adminis-
tration and the start of the PET scan varied between 53 and
110 min (average 64 min). Emission and transmission scan-
ning (68Ge/68Ga rod sources) covered the body from the
proximal femora to the skull base. The scan was performed
with the patient in the supine position, arms down at the
sides. Eleven patients were examined in 3D mode and nine
patients in 2D mode. Transmission time per bed position
was 4 min for both the 2D and 3D scans, while emission
time per bed position was 8 min for the 2D scans and 4 min
for the 3D scans. Overlap between bed positions was 1 cm
for the 2D scans and 1.5 cm for the 3D scans. The effective
axial field of view was 13.75 cm in 2D mode and 12.75 cm
in 3D mode.
PET/MRI
After the first PET scan the patient was transferred to the
adjacent PET/MRI scanner (Ingenuity TOF PET/MRI scan-
ner; Philips Medical Systems, Cleveland, OH). The PET
component of the system features time-of-flight technology,
an axial field of view of 18 cm, 9 cm overlap between bed
positions and a reconstructed isotropic spatial resolution of
about 5.5 mm. The patients were examined in the supine
position, with arms down at the sides. The PET/MRI exam-
ination consisted of a low-resolution nondiagnostic attenu-
ation MR scan of the head, neck and thorax, followed by a
PET scan and a diagnostic MR scan of the head and neck.
The attenuation MR scan is a nondiagnostic T1-weighted
fast field echo scan used for PET attenuation correction. It
covers the head, neck and thorax following the manufac-
turer‘s recommendations. Although the patient is positioned
in a 16-channel phased array neurovascular coil from the
start of the PET/MRI examination, attenuation MR scans are
acquired with the integrated quadrature body coil. An MR-
based attenuation map used for attenuation correction in
PET image reconstruction is created via segmentation of
the attenuation MR image volume into three tissue classes
(air, lung and soft tissue) followed by an assignment of
respective attenuation values (0, 0.022 and 0.096 cm-1)
[11, 12]. The effects of the phased array coil on PET atten-
uation are taken into account via a corresponding vendor-
provided attenuation template, which is included in the final
attenuation image.
The average time between tracer injection and the start of
the second PET scan was 177 min (143–225 min). Three
bed positions were used to cover the complete head and
neck region. Emission time was 6 min for each bed position.
The position of the patient on the scanner table remained
unchanged during the whole examination in order to achieve
optimal coregistration of the PET and MR data.
Total imaging time for the PET/MRI examination was
39 min, including 18 min for the PET scan.
Diagnostic MR images were acquired with a 16-channel
phased array neurovascular coil. The diagnostic MR scan
included short tau inversion recovery (STIR) turbo spin
echo (TSE) images in axial and coronal orientation, T1-
weighted TSE images in axial orientation, T1-weighted
contrast-enhanced TSE images with fat saturation in axial
orientation and T1-weighted contrast-enhanced turbo field
echo images with fat suppression in coronal orientation.
Sequence parameters are summarized in Table 1. Gd-
DTPA (0.2 ml/kg body weight; Magnevist®. Bayer Scher-
ing Pharma, Berlin, Germany) was injected intravenously,
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followed by 20 ml saline. Fused PET/MR images were
produced using the Philips Fusion Viewer software.
Image interpretation
MR images were evaluated on a Philips Extended MR
Workspace (EWS) console by two board-certified radiolog-
ists without access to the PET data. In the event of differing
results, the final decision was made in consensus. Cervical
lymph nodes with the shortest diameter more than 10 mm
were considered malignant [13]. Further imaging findings
regarded as suggestive for malignant lymph node disease
were a spherical lymph node shape [14], nodal necrosis [15]
and irregular lymph node borders [16]. PET scans were
visually evaluated by two board-certified nuclear medicine
physicians without access to the MRI data. Lesions that
appeared to have increased tracer uptake in comparison to
the salivary glands and the muscles were considered malig-
nant [17]. In the event of differing results, the final decision
was made in consensus. PET/MR images were evaluated by
a board-certified radiologist and a board-certified nuclear
medicine physician in consensus.
Both PET datasets were compared visually with a focus on
tumour delineation, the conspicuity of lymph node metastases
and artefacts. The maximum standardized uptake values
(SUVmax) of the tumour and of both cerebellar hemispheres
were determined for both PET datasets using the ROVER®
software package (ABX advanced biochemical compounds,
Radeberg, Germany). The software allows the semiautomatic
analysis of 3D regions of interest, providing parameters in-
cluding metabolically active volume and SUVmax [18].
Statistical analysis
The Wilcoxon matched-pairs test was used to compare the
conventional PET scanner and the PET/MRI system with
regard to the number of lymph nodes with increased FDG
uptake, and the SUVs of the tumour and the cerebellum.
Cohen’s kappa was used to evaluate interrater agreement for
primary tumour detection. In contrast, kappa with linear
weighting was used to assess interrater agreement for lymph
nodes with increased FDG uptake, as in this case a different
number of detected lymph nodes is not equal to complete
disagreement between the readers. Data were analysed using
MedCalc 12.0 (MedCalc Software bvba, Mariakerke, Bel-
gium). A p value <0.05 was considered statistically
significant.
Results
The primary tumour was detected by PET/MRI in 17 of the
20 patients, by PET in 16 and by MRI in 14 (Fig. 1). Both
nuclear medicine physicians evaluating the PET data
detected 16 tumours on both PET datasets. Thus the result-
ing kappa was 1.0 in both cases. One radiologist identified
13 tumours on the MR images, while the second reader
identified 14 tumours on the MR images (interrater agree-
ment κ00.89).
Lymph nodes suspicious for metastatic disease were seen
in 13 patients (Fig. 2).
Using the stand-alone PET scanner, 39 cervical
lymph nodes with increased FDG uptake were detected
visually, and using the PET datasets from the PET/MRI
system, 64 were detected. The calculated interrater reli-
abilities were κ00.91 for the images acquired with the
conventional system (39 vs. 35 lymph nodes with in-
creased FDG uptake) and κ00.93 for the PET images
acquired with the hybrid system (64 vs. 66 lymph nodes
with increased FDG uptake). The numbers of lymph
nodes detected using the two PET datasets differed
significantly (Wilcoxon test, p00.001). No MRI-induced
artefacts were observed in the PET images from the
PET/MR system. There was also no evidence for MR
image artifacts caused by the PET hardware of the PET/
MR system.
SUVmax was evaluated in 16 patients, as in the remaining
4 patients the primary tumour was not detected by PET. The
Table 1 Sequence parameters
Sequence Orientation Field of view
(mm)







STIR_long TE cor Coronal 250×199 30 3 4354 60 512 4 min 47 s
STIR_long TE tra Axial 250×180 30 4 4354 60 512 4 min 21 s
T1W_TSE tra Axial 250×159 24 4 450 9.2 512 3 min 50 s
THRIVE Coronal 250×199 150 2 7.5 3.6 256 3 min 17 s
T1_SPIR CE Axial 250×159 25 4 656 9.2 512 5 min 31 s
FOV field of view; TR repetition time; TE echo time; STIR short-tau inversion recovery; TSE turbo spin echo; THRIVE T1-weighted high-resolution
isotropic volume acquisition; SPIR spectral presaturation with inversion recovery; CE contrast enhanced
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PET/MRI scans yielded a mean SUVmax of 14.3 for the
tumours (95% CI 11.3 to 17.3), while the conventional
PET scans yielded a mean SUVmax of 10.0 (95% CI 7.4 to
12.6) for the same lesions. The mean SUVmax of the cere-
bellum was 10.4 for the PET/MRI scans (95% CI 9.00 to
11.8) and 8.9 for the conventional PET scans (95% CI 8.0 to
9.9). The SUVmax values from the PET/MR scans were
significantly higher than those from the conventional PET
scans for both tumour (p<0.0001) and cerebellum (p0
0.0009).
Tumour resection was performed in 13 patients, laser
excision in 2, laryngectomy in 1, primary radiotherapy
in 2 and palliative systemic therapy in 1. In one patient,
the PET/MRI scan revealed a mass in the lower lobe of
the right lung, which was highly suspicious for malig-
nancy. Histologic samples obtained by bronchoscopy
showed a bronchial carcinoma, while a CT scan of the
lung showed additional metastases in both lungs. An-
other patient had a small pulmonary node in the upper
lobe of the right lung, which had strong FDG uptake
and was rated as a metastasis. In this patient, a partial
resection of the upper lobe was performed. The nodule
turned out to be an aspergilloma. The patient was trea-
ted by tumour resection and neck dissection.
Discussion
Staging of head and neck cancer requires imaging of the
whole head and neck region. The current study demon-
strated that comprehensive PET/MR of the head and
neck region is feasible with a whole-body PET/MR
system without impairment of PET or MR image qual-
ity. Early PET/MR systems were essentially restricted to
brain examinations because of the limited axial field of
view of the available PET inserts. The feasibility of
PET/MRI of the head and upper neck using this scanner
type in patients with nasopharyngeal carcinoma was
previously demonstrated [19]. However, the imaging of
the head and upper neck only is insufficient in patients
Fig. 1 Squamous cell
carcinoma of the tongue in a
55-year-old man. a Axial T1-
weighted TSE image. The tu-
mour is not detectable due to
susceptibility artefacts caused
by dental implants (arrow-
heads). b Axial STIR TSE
image showing nearly identical
susceptibility artefacts
(arrowheads). c Maximum
intensity projection image of
the PET dataset showing the
tumour (arrow) and a lymph
node metastasis (arrowhead). d
Axial fused PET/MR image.
The tumour is clearly visible
(arrow)
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with malignancies of the oral cavity, oro- and hypophar-
ynx and larynx. In these patients, either the primary
tumour (e.g. carcinoma in the hypopharynx or larynx)
or cervical lymph node metastases of the lower neck
will not be detected. In contrast, the current study
demonstrated the feasibility of an imaging protocol that
allows evaluation of the whole head and neck region, in
an analogous manner to MRI scans used in clinical
routine.
As PET/MR is a new modality, data concerning image
quality of PET/MRI scans are scarce. Promising results
regarding PET image quality have already been reported
by Boss et al. for PET/MRI examinations of the brain
[20]. These authors described streak artefacts on PET
images, which are related to the design of early simulta-
neous PET/MRI systems, and can be reduced by filtering. In
the current study, no such artefacts were observed. The
improved signal-to-noise-ratio achieved with time-of-flight
PET is a significant advantage of the sequential scanner
design. While signal-to-noise-ratio improvement is most
pronounced in the imaging of abdominal lesions, it has also
been documented for other body parts, including the neck
[21]. Time-of-flight PET is currently not feasible with si-
multaneous PET/MR systems because of limitations of the
avalanche photodiodes used [22]. In contrast, sequential
designs utilize photomultiplier tubes which allow full ad-
vantage to be taken of the excellent timing behaviour of
state-of-the-art scintillator crystals such as LYSO [23].
Longer acquisition times are a potential disadvantage of
sequential PET/MRI systems in comparison to simultaneous
PET/MR systems. While this might be a significant factor in
brain examinations that include dynamic PET measure-
ments of substantial duration, the increase in scan time for
the head and neck region is much less pronounced. In the
present study PET was responsible for 46% of the total
acquisition time (18 min out of 39 min). The choice of
MR sequences has a large impact on PET/MRI scan time.
In our study the MRI protocol was nearly identical to the
standard head/neck MRI protocol used in our hospital. More
clinical data are needed to decide if some MRI sequences
can be omitted from the PET/MRI protocol and thus reduce
scan time.
Significantly higher tumour SUV(max) values were found
with the PET/MRI scans than with the first PET scans
(60 min after injection). Although the comparison of SUV
values determined with different scanner types is problem-
atic, the leading factor for this effect can be attributed to
tumour pathophysiology. Tumour uptake of FDG increases
with time, leading to higher SUVmax values at later time
points [24]. The increase in cerebellar SUVmax values was
less pronounced, possibly due to an already physiologically
decreasing FDG uptake of brain tissue at later time points
[25]. Another possible factor causing SUV differences may
be the attenuation correction methods used in conventional
PET and PET/MRI. Comparing PET and PET/CT, Naka-
moto et al. [26] found slightly higher radioactive concen-
trations for CT-corrected emission images than for Ge-
corrected images. Later studies, however, did not find sig-
nificant differences between SUVs calculated with PET and
PET/CT [27]. Currently, the influence of MRI-based atten-
uation correction on SUVs is being studied and its magni-
tude has not been clarified.
The number of lymph nodes with increased FDG
uptake detected using the PET dataset from the hybrid
system was significantly higher than the number from
the stand-alone PET scanner. This observation can be
explained mainly by a combination of two beneficial
effects. First, the stand-alone PET scans were performed
earlier than the PET/MRI scans (64 min vs. about
177 min after injection on average). An extended FDG
uptake period before the PET/MRI scan leads to an
increased contrast of FDG-avid structures relative to
Fig. 2 Histologically proven
lymph node metastasis in a 60-
year-old man with a squamous
cell carcinoma of the right piri-
form sinus. a Axial fused PET/
MR image. The metastatic
lymph node is easily recogniz-
able due to increased FDG up-
take (arrow). b Axial STIR TSE
image. In this patient the me-
tastasis was also detected by
MRI alone (arrow)
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the surrounding normal tissue since the contribution of
free FDG in tissue to the image signal is reduced at
later times. Moreover, the spatial resolution of the PET
images delivered by PET/MRI systems is superior to
that delivered by stand-alone PET systems, because of
reduced partial volume effects and signal loss in small
structures. Both factors increase detectability of small lesions
by maintaining a sufficient target-to-background contrast.
While PET/MRI is not intended to be a replacement for
PET/CT, it has the potential to improve diagnostic imaging
in patients in whom the soft tissue contrast provided by CT
is deemed insufficient, for example in head and neck or
pelvic tumours. Furthermore, PET/MRI has the potential
to significantly reduce radiation exposure in comparison to
PET/CT. Further studies are needed to evaluate the clinical
role of PET/MRI in head and neck cancer.
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